Peptide Initiative

Peptides · Peptide comparison

Dihexa vs N-Acetyl Selank

Angiotensin IV-derived oligopeptide that potentiates hepatocyte growth factor to drive synaptogenesis and cognitive enhancement with extraordinary potency

Acetylated tuftsin analogue heptapeptide with enhanced stability and anxiolytic, nootropic, and immunomodulatory properties acting through GABAergic modulation and BDNF upregulation

  • Cognitive
  • Cognitive

At a glance

Quick comparison

Dose rangeDihexa8–20 mgN-Acetyl Selank300–900 mcg/day
FrequencyDihexaOnce dailyN-Acetyl SelankOnce daily
AdministrationDihexaOral (capsule/tablet)N-Acetyl SelankIntranasal spray
Cycle lengthDihexa4-6 weeksN-Acetyl Selank4-6 weeks
Onset speedDihexaModerate (1-2 weeks)N-Acetyl SelankRapid (hours to days)
Evidence levelDihexaPreclinical only — animal and cell-culture studies; no human trialsN-Acetyl SelankLimited human trials

Efficacy

Benefit ratings

Cognitive

Dihexa95%
N-Acetyl SelankNo recorded rating

Healing & Recovery

Dihexa60%
N-Acetyl SelankNo recorded rating

Anti-Aging

Dihexa55%
N-Acetyl SelankNo recorded rating

Anxiety Relief

DihexaNo recorded rating
N-Acetyl Selank94%

Brain Health

DihexaNo recorded rating
N-Acetyl Selank91%

Stress Resilience

DihexaNo recorded rating
N-Acetyl Selank88%

Technical data

Compound specifications

Dihexa

Molecular formula
C27H44N4O5
Molecular weight
504.7 g/mol
Half-life
~12 days (following IV administration in rats)
Bioavailability
Orally active and blood-brain barrier permeable — specific oral bioavailability percentage not published
CAS number
1401708-83-5

N-Acetyl Selank

Molecular formula
C35H59N11O10
Molecular weight
793.9 g/mol
Half-life
Extended compared to native Selank (~7-10 min plasma half-life); exact half-life of N-Acetyl form not published but estimated 2-3x longer
Bioavailability
Enhanced intranasal and subcutaneous bioavailability compared to native Selank due to N-acetylation protecting against aminopeptidase degradation
CAS number
Not assigned (N-Acetyl Selank); 129954-34-3 (parent Selank)

Protocols

Dosing compared

Dihexa

Oral

  • 5–8 mgOnce daily · 2–4 weeksLower starting amount reported in practice. Dihexa has no human clinical trials, so all amounts come from animal research and community use [2][4].
  • 8–20 mgOnce daily · 4–6 weeksCommonly reported daily range in practice for cognitive support [2][4].
  • 20–45 mgOnce daily · 4–6 weeks, then reassessUpper end of amounts reported in practice. No long-term human safety data exists, so this should be approached with caution [2][4].

Sublingual

  • 5–15 mgOnce daily · 4–6 weeksHeld under the tongue as an alternative to swallowing; amounts reported in practice are similar to oral use [4].

Topical

  • 5–15 mg in DMSO carrierOnce daily · 4–6 weeksApplied to the skin in a DMSO solution to help absorption; used in practice as a non-oral option [4].

N-Acetyl Selank

Intranasal

  • 250-300 mcg/dayDivided 2-3 times daily · 1-2 weeks initialLower end of the intranasal range used in Russian anxiolytic research; intranasal is the optimal CNS-delivery route for Selank [1][6].
  • 300-900 mcg/dayDivided 2-3 times daily (100-300 mcg per dose) · 2-4 weeks per courseDaily intranasal range documented in Russian GAD trials, with anxiolytic effects comparable to medazepam [6].
  • Up to 2700 mcg/dayDivided 2-3 times daily · 2-4 weeks per courseUpper intranasal dose reported in a generalized anxiety disorder cohort [6]; used short-course.

Applications

Best suited for

Dihexa

Age-Related Cognitive Decline
Dihexa directly addresses the synaptic loss that underlies age-related cognitive decline by building new functional synaptic connections in the hippocampus. Animal studies demonstrate restored spatial learning in aged rats, [6] making it a compelling candidate for combating memory loss associated with aging.
Neuroplasticity Enhancement
Unlike nootropics that work through neurotransmitter modulation, dihexa drives physical neuroplasticity — the formation of new dendritic spines and synapses. [6] This makes it ideal for individuals looking to enhance their brain's capacity for learning and adaptation at a structural level.
Neurodegenerative Disease Research
Preclinical evidence in APP/PS1 Alzheimer's mice and scopolamine-induced amnesia models [4][6] positions dihexa as a leading research compound for neurodegenerative disease. It is patented for potential use in Alzheimer's and Parkinson's diseases, with ongoing interest from the research community.
Advanced Nootropic Stacking
Dihexa's unique mechanism (HGF/c-Met potentiation) is complementary to most other nootropic mechanisms, making it an excellent addition to advanced cognitive enhancement protocols when combined with choline donors, racetams, or adaptogens.

N-Acetyl Selank

Anxiolytic support without the sedation, tolerance, or dependence associated with benzodiazepines
N-Acetyl Selank is particularly well-suited for individuals focused on anxiolytic support without the sedation, tolerance, or dependence associated with benzodiazepines. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6][13].
Cognitive enhancement through BDNF-mediated neuroplasticity
N-Acetyl Selank is particularly well-suited for individuals focused on cognitive enhancement through bdnf-mediated neuroplasticity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Stress resilience and emotional regulation in high-demand environments
N-Acetyl Selank is particularly well-suited for individuals focused on stress resilience and emotional regulation in high-demand environments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [16].
Complementary nootropic in cognitive stacks targeting multiple neurotransmitter systems
N-Acetyl Selank is particularly well-suited for individuals focused on complementary nootropic in cognitive stacks targeting multiple neurotransmitter systems. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Dihexa

Common

  • Headache
  • Vivid dreams or altered sleep patterns
  • Emotional sensitivity
  • Mild fatigue during adjustment

Uncommon

  • Gastrointestinal discomfort

Serious

  • Theoretical oncogenic risk from c-Met activation

N-Acetyl Selank

Common

  • Nasal irritation
  • Transient headache
  • Mild drowsiness or fatigue
  • Vivid dreams
  • Appetite changes

Uncommon

  • Nasal congestion or epistaxis

Serious

  • Allergic reaction

Research status

Safety & evidence

Dihexa

Evidence level
Preclinical only — animal and cell-culture studies; no human trials
FDA status
Research compound
Safety overview
Dihexa has demonstrated a favorable safety profile in published animal studies, with no reported tumorigenic effects or organ toxicity at cognitive-enhancing doses. However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist. [7] The primary theoretical safety concern is sustained activation of the HGF/c-Met proto-oncogenic pathway, which could theoretically promote tumor initiation or growth. [7] The extremely long half-life (~12 days) [6][7] raises additional concerns about compound accumulation with chronic daily dosing. Anecdotal reports from the nootropics community generally describe good tolerability at doses of 5-20 mg daily, with headaches and vivid dreams as the most commonly reported effects.

Contraindications

  • Known or suspected malignancy — c-Met/HGF pathway activation may promote tumor growth
  • Pregnancy and breastfeeding — no safety data available
  • History of cancer, particularly HGF/c-Met-driven tumors (hepatocellular, gastric, lung)
  • Severe hepatic impairment

N-Acetyl Selank

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
N-Acetyl Selank demonstrates favorable safety in preclinical and clinical research with no serious adverse events at therapeutic doses. [11][13] The acetylation modification enhances metabolic stability compared to native Selank while maintaining its anxiolytic efficacy. Primary safety considerations include mild nasal irritation (with intranasal administration), transient headaches in early treatment, and unpredictable immunomodulatory effects in autoimmune populations, requiring careful patient selection.

Contraindications

  • Known hypersensitivity to Selank, tuftsin, or any component of the formulation
  • Pregnancy and breastfeeding — insufficient safety data
  • Active autoimmune disorders — immunomodulatory effects may be unpredictable
  • Concurrent use of immunosuppressive therapy — potential for immune system interference

Decision guide

Which is right for you?

Dihexa

Choose Dihexa if…

  • Cognitive enhancement and memory consolidation in age-related decline
  • Supporting neuroplasticity and new synaptic connection formation
  • Research into neurodegenerative disease therapeutics (Alzheimer's, Parkinson's)
  • Nootropic stacking for individuals seeking enhanced learning capacity

N-Acetyl Selank

Choose N-Acetyl Selank if…

  • Anxiolytic support without the sedation, tolerance, or dependence associated with benzodiazepines
  • Cognitive enhancement through BDNF-mediated neuroplasticity
  • Stress resilience and emotional regulation in high-demand environments
  • Complementary nootropic in cognitive stacks targeting multiple neurotransmitter systems